ArticleLaryngoscope investigative otolaryngology2020
Topical fibroblast growth factor-2 for treatment of chronic tympanic membrane perforations.
Article in Laryngoscope investigative otolaryngology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06448039 (In-office Repair of Chronic Tympanic Membrane Perforations), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
In-office Repair of Chronic Tympanic Membrane Perforations
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- The effectiveness and safety of growth factors in the treatment of tympanic membrane perforations: a systematic review and meta-analysis of randomized controlled trials.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022Pooled it
- Comparative Study of Tympanic Membrane Regeneration Therapy for Chronic Otitis Media.The Laryngoscope · 2026Article
- Adjunctive Serum Drops to Paper Patch for Tympanic Membrane Perforation.The Annals of otology, rhinology, and laryngology · 2026Article
- Efficacy of Concentrated Growth Factors in Treating Tympanic Membrane Perforation in Guinea Pigs.The journal of international advanced otology · 2025Article
- Tough and self-adhesive zwitterionic hydrogels with mechano-responsive release of bFGF for tympanic membrane repair.Materials today. Bio · 2024Article
- Searching for a Better Animal Model for Chronic Tympanic Membrane Perforation.Journal of personalized medicine · 2024Article
- In Vitro Assessment of Wound-Healing Efficacy of Stabilized Basic Fibroblast Growth Factor (FGF-2) Solutions.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Overcoming barriers: a review on innovations in drug delivery to the middle and inner ear.Frontiers in pharmacology · 2023Review
- Molecular and Clinical Significance of Fibroblast Growth Factor 2 in Development and Regeneration of the Auditory System.Frontiers in molecular neuroscience · 2021Review
- Topical Application of bFGF Alone for the Regeneration of Chronic Tympanic Membrane Perforations: A Preliminary Case Series.Stem cells international · 2021Article
- FGF2 and EGF for the Regeneration of Tympanic Membrane: A Systematic Review.Stem cells international · 2021Review
- Topical fibroblast growth factor-2 for treatment of chronic tympanic membrane perforations.Laryngoscope investigative otolaryngology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo determine the efficacy of fibroblast growth factor-2 (FGF-2) in treating chronic nonhealing tympanic membrane (TM) perforations.
methodDouble-blinded, randomized placebo controlled phase 2 clinical trial for patients with chronic TM perforations of more than 3 months duration with a cross-over arm. Patients received either FGF-2 or placebo (sterile water) saturated gelatin sponge in the perforation after rimming the perforation under topical anesthesia. The perforation was then covered with Tisseel fibrin glue. The primary endpoint was complete closure of the TM perforation. Secondary end points included change in hearing and partial TM closure rates. The TM was examined every 3 weeks with otoendoscopy for closure. The treatment was repeated if there was incomplete closure every 3 weeks up to a total of three treatments per arm.
resultsSeventy four patients were recruited for the study. Fifty seven met eligibility criteria and fifty four completed the study. Ten of 14 perforations closed completely in the placebo group (71.4%) and 23 of 40 perforations closed completely in the FGF-2 treatment group (57.5%),
conclusionNo statistically significant difference in tympanic membrane perforation closure rate was found between the FGF-2 and placebo groups. There were no differences in hearing outcomes between the groups. LEVEL OF EVIDENCE: 1b.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.